Trials / Unknown
UnknownNCT05150405
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
An Open, Dose-escalating Phase Ia Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLF31907 Injection in Patients With Advanced Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and tolerability of QLF31907 injection, to identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), and determine the recommended phase Ib dose(RPIbD) and recommended phase II dose (RP2D)in patients with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLF31907 | In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most. |
Timeline
- Start date
- 2021-10-19
- Primary completion
- 2024-03-31
- Completion
- 2024-06-01
- First posted
- 2021-12-09
- Last updated
- 2024-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05150405. Inclusion in this directory is not an endorsement.